What are the recommended treatments for dry mouth (xerostomia) in adults?

Treatment for Dry Mouth

For dry mouth in adults, start with basic oral care protocols including sodium bicarbonate mouthwash 4-6 times daily, then add topical treatments like pilocarpine mouthwash, 1% malic acid, or saliva substitutes containing xylitol, and reserve systemic cholinergic agents (pilocarpine or cevimeline) for severe cases unresponsive to topical therapy 1, 2.

Algorithmic Treatment Approach

First-Line: Basic Oral Care and Topical Measures

• Sodium bicarbonate mouthwash: Use a bland, non-alcoholic formulation 4-6 times daily for prevention; increase frequency up to hourly for active symptoms 1
• Saliva substitutes or stimulants: Sugarless chewing gum or candy, salivary substitutes, or sialogogues for symptomatic relief 1
• Topical agents with proven efficacy: Pilocarpine mouthwash/mucoadhesive tablets, 1% malic acid, or thyme-honey mouth rinse provide significant symptom reduction (Z = 5.78; p < 0.001) 2

The most recent 2025 meta-analysis demonstrates that topical applications effectively relieve xerostomia symptoms in older adults, though they don't significantly improve salivary flow rates 2. This is clinically acceptable since symptom relief directly impacts quality of life, which is the priority outcome.

Second-Line: Address Underlying Causes

• Medication review: The most common cause of dry mouth is medication use, particularly anticholinergic drugs and polypharmacy 3, 4
• Dose reduction or substitution: Switch to medications with fewer xerogenic side effects when clinically feasible 4
• Treat dehydration: Address fluid intake, alcohol, and caffeine consumption 3
• Evaluate systemic diseases: Screen for Sjögren's disease and other autoimmune conditions 3

Third-Line: Systemic Pharmacotherapy

Reserve for severe cases unresponsive to topical measures:

• Pilocarpine: Parasympathomimetic agent with potent muscarinic, cholinergic salivation-stimulating properties 4
• Cevimeline: Quinuclidine analogue with similar therapeutic effects to pilocarpine 4, 5

Critical caveat: Both agents cause significant cholinergic side effects including nausea, emesis, and bronchoconstriction, requiring close supervision especially in older adults 4. Use only when topical measures fail and benefits outweigh risks.

Special Considerations for Cancer Patients

For patients receiving targeted cancer therapy or radiation:

• Implement oral care protocols prophylactically before treatment initiation 1
• IMRT (intensity-modulated radiation therapy) significantly reduces xerostomia compared to conventional radiotherapy in head and neck cancer (39.3% vs. 82.1% severe xerostomia at 1 year; P = .001) 6
• Mean parotid dose reduction from 62 Gy to 32 Gy with IMRT preserves salivary function 6

Pain Management When Needed

If oral dryness causes pain or discomfort:

• Topical anesthetics: Viscous lidocaine 2% before painful activities like eating 1
• Topical NSAIDs: Amlexanox 5% oral paste for moderate pain 1
• Systemic analgesics: Follow WHO pain ladder; consider alternative routes (transdermal, intranasal) if oral administration is compromised 1

Common Pitfalls to Avoid

1. Don't wait for complications: Chronic untreated xerostomia leads to dental caries, periodontal disease, infections, dysphagia, malnutrition, and depression 3, 4, 5
2. Don't overlook medication causes: Always conduct comprehensive medication review before adding new treatments 3, 4
3. Don't assume topical treatments will improve salivary flow: They provide symptom relief without necessarily increasing saliva production, which is still clinically valuable 2
4. Don't use systemic cholinergic agents as first-line: Reserve for refractory cases due to significant side effect burden 4

Evidence Quality Note

The 2015 ESMO guidelines 1 provide expert consensus recommendations for cancer-related xerostomia, while the 2025 systematic review 2 offers the highest quality recent evidence for topical treatments, though it notes moderate-to-high risk of bias in included studies. The convergence of guideline recommendations and recent meta-analytic data supports the stepwise approach prioritizing topical over systemic therapy.